Anti-IL-6 receptor monoclonal antibody
Satralizumab
Brand names: Enspryng
Adult dose
Dose: 120mg SC at weeks 0, 2, 4 then every 4 weeks
Route: SC
Frequency: q4w (after loading)
Clinical pearls
- Aquaporin-4 antibody-positive NMOSD
- Per NICE TA849
Contraindications
- Active serious infection
- Active hepatitis B
- Hypersensitivity
Side effects
- Infections
- Hepatic transaminitis
- Hyperlipidaemia
- Reduced neutrophils
- Injection-site reactions
Interactions
- Live vaccines
- Other immunosuppressives
- CYP substrates (IL-6 normalisation alters CYP)
Monitoring
- LFTs
- Lipids
- FBC
- Infections
Reference: BNF; NICE TA849; SmPC; https://bnf.nice.org.uk/drugs/satralizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale · Neuromuscular
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS